Trial Profile
A study investigating the effect of ribavirin plasma concentration on sustained virological response on patients with HCV genotype 1 receiving telaprevir or boceprevir combination therapy with ribavirin plus pegylated interferon alpha 2a
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Dec 2015
Price :
$35
*
At a glance
- Drugs Boceprevir (Primary) ; Ribavirin (Primary) ; Telaprevir (Primary) ; Peginterferon alfa-2a
- Indications Hepatitis C
- Focus Therapeutic Use
- 21 Dec 2015 New trial record